Azienda Sanitaria Universitaria Friuli Centrale | Rheumatology Department

Research site

(Unclaimed)

Location

Piazzale Santa Maria della Misericordia 15, Udine, Udine, Italy

Site insights

Top conditions

Top treatments

Encorafenib

Binimetinib

5-Fluorouracil

THR-149

Solu-Medrol

Trifluridine

Doxorubicin

Methylprednisolone

Dostarlimab

Trastuzumab

Parent organization

This site is a part of Azienda Sanitaria Universitaria Friuli Centrale

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 19 total trials

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the...

Active, not recruiting

Melanoma

Drug: Binimetinib

Drug: Encorafenib

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Enrolling

Diffuse Large B-cell Lymphoma (DLBCL)

Drug: Doxorubicin

Drug: Prednisone/Prednisolone

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant s...

Active, not recruiting

Melanoma

Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib

Drug: Encorafenib and Binimetinib

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line (DOMENICA)

Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficien...

Enrolling

Endometrial Cancer

Drug: Carboplatin-Paclitaxel

Drug: Dostarlimab

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (ERASE-CRC)

The aims of this study are to evaluate if an intensified adjuvant treatment with FOLFOXIRI could increase the rate of cases with undetectable ct-DNA...

Enrolling

RAS Wild-type Colon Cancer

Stage II Colon Cancer

Drug: 5-Fluorouracil continuous infusion FOLFOXIRI schedule

Drug: L-Leucovorin

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclis...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Teclistamab